Fidelity Investments’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Fidelity Investments’s Portfolio EVFM Stock Details EVFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2	Closed	–	–	5749
2022 Q1	$0	Buy	+2	New	+$13	﹤0.01%	5707
2021 Q1	–	Sell	-33	Closed	-$1K	–	4729
2020 Q4	$1K	Buy	+33	New	+$1.19K	﹤0.01%	3768
2020 Q3	–	Sell	-15	Closed	-$1K	–	4126
2020 Q2	$1K	Buy	+15	New	+$1.01K	﹤0.01%	3524

Other funds holding EVFM

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $486M AUM 50.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Fidelity Investments's EVFM Position: Q2 2022 in Review

Fidelity Investments sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2022, closing a stake of 2 shares.

Fidelity Investments first reported a position in EVFM in Q2 2020 and held it in 3 quarters. The position peaked at $1K in Q4 2020. 44 funds tracked by Wall St. Rank hold EVFM as of Q2 2022.

Fidelity Investments reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Fidelity Investments sold 2 Evofem Biosciences, Inc. Common Stock shares in Q2 2022.
Fidelity Investments first reported a position in Evofem Biosciences, Inc. Common Stock in Q2 2020 and held it in 3 quarters.
Fidelity Investments's Evofem Biosciences, Inc. Common Stock position peaked at $1K in Q4 2020.
44 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2022.

Based on Fidelity Investments's 13F filing for Q2 2022, filed 12 Aug 2022.